Day: March 4, 2021

HALIFAX, Nova Scotia, March 04, 2021 (GLOBE NEWSWIRE) — N.W. Fulcher Limited (“Fulcher”) announces that it has acquired 2,948,076 common shares (“Common Shares”) of Nova Leap Health Corp (TSXV: NLH) (“Nova Leap”), with its head office at 5003-7071 Bayers Road, Halifax, Nova Scotia, B3L 2C2, representing approximately 4.21% of the Common Shares issued and outstanding. Fulcher is owned and controlled by Wayne Fulcher.On January 6, 2020 and February 5, 2020, Fulcher acquired 250,000 and 775,000 Common Shares, respectively, pursuant to the exercise of common share purchase warrants (the “Warrants”) at an exercise price of $0.35 and $0.375 per share, respectively (the “2020 Transactions”). On March 3, 2021, Fulcher acquired 1,923,076 Common Shares pursuant to the forced conversion of an unsecured convertible debenture issued on December...

MONCTON, New Brunswick, March 04, 2021 (GLOBE NEWSWIRE) — Major Drilling Group International Inc. (TSX: MDI), a leading provider of specialized drilling services to the mining sector (“Major Drilling” or the “Company”), today reported results for its third quarter of fiscal year 2021, ended January 31, 2021.HighlightsRevenue up 23% from Q3 2020, driven primarily by increased gold drilling activityEBITDA (1) up 226% compared to same period last year, despite heavy start-up costsImproved net cash position (2) by $6.6 million to $14.2 millionIncreased training and recruiting efforts well under way, in anticipation of increased demand in Q4 and beyond“We are pleased by the level of activity generated this quarter, despite the anticipated cyclicality of seasonal shutdown. November was a particularly good month and continued the progression...

CALGARY, Alberta, March 04, 2021 (GLOBE NEWSWIRE) — ClearStream Energy Services Inc. (“ClearStream” or the “Company”) (TSX: CSM) today announced its results for the three and twelve months ended December 31, 2020. All amounts are in Canadian dollars and expressed in thousands of dollars unless otherwise noted.“EBITDAS” and “Adjusted EBITDAS” are not standard measures under IFRS. Please refer to the Advisory regarding Non-Standard Measures at the end of this press release for a description of these items and limitations of their use.“With the arrival of the second wave of the COVID-19 pandemic in the fourth quarter, activity levels returned to a level similar to the second quarter when economic activity was constrained by the public health measures as governments responded and caused customers to remain cautious regarding...

Stellantis announces conditional distribution of Faurecia shares and cashAmsterdam, March 4, 2021 – Stellantis N.V. (NYSE / MTA / Euronext Paris: STLA) (“Stellantis”) announced today a conditional distribution by Stellantis to the holders of its common shares of up to 54,297,006 ordinary shares of Faurecia S.E. (“Faurecia”) and up to €308 million in cash, being the proceeds received by Peugeot S.A. from the sale of ordinary shares of Faurecia in October 2020, payable to holders of Stellantis common shares of record as of Tuesday, March 16, 2021, pursuant to a capital reduction (the “Distribution”).Payment of the Distribution is conditional upon the further announcement that the Distribution has been approved by the Extraordinary General Meeting of Shareholders of Stellantis to be held on March 8, 2021 and that certain Dutch law formalities...

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) — Haymaker Acquisition Corp. III (the “Company”) (NASDAQ: HYACU) today announced that it closed its initial public offering of 30,000,000 units. The offering was priced at $10.00 per unit generating total gross proceeds of $300,000,000.Of the proceeds received from the consummation of the initial public offering and a simultaneous private placement of warrants, $300,000,000 (or $10.00 per unit sold in the public offering) was placed in trust.The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to acquire and operate a business in the consumer or consumer-related products and services industries....

TORONTO, March 04, 2021 (GLOBE NEWSWIRE) — United Corporations Limited (TSX:UNC) (TSX:UNC.PR.A) (TSX:UNC.PR.B) (TSX:UNC.PR.C) (the “Company”) announced today that the Toronto Stock Exchange (the “Exchange”) has accepted a notice filed by the Company of its intention to proceed with the renewal of its Normal Course Issuer Bid (the “Bid”) to be transacted through the facilities of the Exchange or through alternative Canadian trading systems.The notice provides that the Company may, during the 12-month period commencing March 9, 2021 and ending March 8, 2022, purchase up to 604,924 common shares in the capital of the Company (“Shares”) in total, being approximately 5% of the total number of 12,098,493 Shares outstanding as at March 2, 2021. The price which the Company will pay for any such Shares will be the prevailing market price at...

FORT MYERS, Fla., March 04, 2021 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announced that John Kiernan, the Company’s President and Chief Executive Officer, and Richard Rallo, the Company’s Senior Vice President and Chief Financial Officer, will participate at the 33rd Annual ROTH Conference, to be held virtually March 15-17, 2021.The Company will be participating in virtual one-on-one and small group meetings on Monday, March 15, 2021 and Tuesday, March 16, 2021. To schedule a meeting with Alico, please contact your ROTH sales representative.About AlicoAlico, Inc. primarily operates two divisions: Alico Citrus, one of the nation’s largest citrus producers, and Land Management and Other Operations, which includes environmental services, land leasing and related support operations. Learn more...

STAMFORD, Conn., March 04, 2021 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (NASDAQ: EGLE) (“Eagle Bulk” or the “Company”), one of the world’s largest owner-operators within the Supramax/Ultramax drybulk segment, today reported financial results for the three months and year ended December 31, 2020.Highlights for the Quarter:Revenues, net of $75.2 millionTCE revenues (1) for the quarter equated to $47.9 million.Achieved TCE (1) of $11,190/day for the quarter versus the Adjusted net BSI (2) at $10,229/dayRealized a net income of $0.1 million, or $0.01 per basic and diluted shareAdjusted EBITDA(1) of $22.0 millionRaised $23.5 million, net, in new equity on December 18, 2020Executed agreements to purchase three modern scrubber-fitted SDARI-64 Ultramax bulkcarriers constructed at Chengxi Shipyard Co. Ltd. for a total purchase price...

Recrutement en cours dans 3 essais cliniques de Phase 1 à escalades de doses BALLI-01 pour les patients atteints de LLA à cellules B en rechute ou réfractaire, AMELI-01 pour les patients atteints de LAM en rechute ou réfractaire et MELANI-01 pour les patients atteints de MM en rechute ou réfractaire, dans 7 grands centres cliniques américainsCellectis a présenté oralement les premiers résultats de son essai clinique de Phase 1 BALLI-01 évaluant le produit candidat UCART22 chez les adultes atteints de LLA à cellules B en rechute ou réfractaire lors de la conférence annuelle 2020 de l’American Society of Hematology (ASH)Programmes en partenariat : Allogene Therapeutics a présenté les premiers résultats de son étude clinique de Phase 1 ALPHA évaluant le produit candidat ALLO-501 dans la NHL en rechute ou réfractaire à la conférence...

Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centersPreliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual MeetingPartner Allogene Therapeutics presented initial results from Phase 1 ALPHA clinical study of licensed ALLO-501 in r/r NHL at 2020 ASCO Annual Meeting and from Phase 1 UNIVERSAL clinical study of licensed ALLO-715 in r/r MM at 2020 ASH Annual MeetingNew collaboration with Cytovia Therapeutics, Inc. to develop 5 TALEN® gene-edited iPSC-derived NK and CAR NK cell programs, including solid tumor targetsCompleted construction of in-house manufacturing site in Paris, France; with manufacturing of...